Hansa Biopharma publishes Annual Report 2021
Lund, Sweden April 7, 2022 Hansa Biopharma AB “Hansa” (Nasdaq Stockholm: HNSA), a pioneer in enzyme technology for rare immunological conditions, today announced the release of the Annual Report 2021 Søren Tulstrup, President and CEO of Hansa Biopharma, comments: 2021 was, overall, a transformative and successful year for Hansa as we advanced into a fully integrated, commercial-stage biopharmaceutical company following the commercial launch in Europe of Idefirix[®] (imlifidase), for desensitization of highly sensitized kidney transplant patients incompatible to a deceased donor.